ID: ALA3822778

Max Phase: Preclinical

Molecular Formula: C151H232N42O48

Molecular Weight: 3403.76

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCCCC(NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O

Standard InChI:  InChI=1S/C151H232N42O48/c1-18-22-39-88(173-130(221)91(44-46-113(204)205)174-138(229)102(60-115(208)209)185-145(236)106(68-195)188-134(225)95(52-80-34-25-23-26-35-80)179-144(235)105(67-194)170-112(203)66-165-127(218)101(59-114(206)207)169-111(202)65-164-126(217)85(153)55-83-64-161-69-166-83)128(219)181-100(58-110(157)201)143(234)193-122(79(17)197)150(241)191-120(75(13)21-4)148(239)186-93(50-71(7)8)133(224)184-104(62-117(212)213)140(231)182-98(56-108(155)199)136(227)176-92(49-70(5)6)132(223)168-76(14)124(215)167-77(15)125(216)172-89(42-33-48-162-151(159)160)129(220)183-103(61-116(210)211)139(230)178-96(53-81-36-27-24-28-37-81)142(233)190-119(74(12)20-3)147(238)187-99(57-109(156)200)137(228)180-97(54-82-63-163-86-40-30-29-38-84(82)86)135(226)177-94(51-72(9)10)141(232)189-118(73(11)19-2)146(237)175-90(43-45-107(154)198)131(222)192-121(78(16)196)149(240)171-87(123(158)214)41-31-32-47-152/h23-30,34-38,40,63-64,69-79,85,87-106,118-122,163,194-197H,18-22,31-33,39,41-62,65-68,152-153H2,1-17H3,(H2,154,198)(H2,155,199)(H2,156,200)(H2,157,201)(H2,158,214)(H,161,166)(H,164,217)(H,165,218)(H,167,215)(H,168,223)(H,169,202)(H,170,203)(H,171,240)(H,172,216)(H,173,221)(H,174,229)(H,175,237)(H,176,227)(H,177,226)(H,178,230)(H,179,235)(H,180,228)(H,181,219)(H,182,231)(H,183,220)(H,184,224)(H,185,236)(H,186,239)(H,187,238)(H,188,225)(H,189,232)(H,190,233)(H,191,241)(H,192,222)(H,193,234)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H,212,213)(H4,159,160,162)/t73-,74-,75-,76-,77-,78+,79+,85-,87-,88?,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99+,100-,101-,102-,103-,104-,105-,106-,118-,119-,120-,121-,122-/m0/s1

Standard InChI Key:  DMRADHQGBFFENY-QKWRWFDPSA-N

Associated Targets(Human)

Glucagon-like peptide 2 receptor 293 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Glucagon-like peptide 1 receptor 111429 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Glucagon receptor 2563 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 3403.76Molecular Weight (Monoisotopic): 3401.7004AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Wiśniewski K, Sueiras-Diaz J, Jiang G, Galyean R, Lu M, Thompson D, Wang YC, Croston G, Posch A, Hargrove DM, Wiśniewska H, Laporte R, Dwyer JJ, Qi S, Srinivasan K, Hartwig J, Ferdyan N, Mares M, Kraus J, Alagarsamy S, Rivière PJ, Schteingart CD..  (2016)  Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.,  59  (7): [PMID:26986178] [10.1021/acs.jmedchem.5b01909]

Source